Navitoclax-piperazine

SKU: orb1309354

Description

Navitoclax-piperazine, also known as ABT-263-piperazine, is a potent and selective BCL-XL inhibitor. It is widely used in oncology research, demonstrating efficacy in inducing apoptosis in cellular assays and showing activity in preclinical in vivo models of hematologic cancers.

Research Area

Pharmacology & Drug Discovery

Images & Validation

−

Key Properties

−

CAS Number	2143096-93-7
MW	973.63
Purity	99.82% (May vary between batches)
Formula	C₄₇H₅₆ClF₃N₆O₅S₃
SMILES	CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCNCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1
Target	Ligands for Target Protein for PROTAC,Bcl-2 Family
Solubility	10% DMSO+90% Corn Oil:3.3 mg/mL (3.39 mM);DMSO:250 mg/mL (256.77 mM)

Storage & Handling

−

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

ABT-263-piperazine, B-cell, Bcl-xL, Bcl-2 Family, Ligands for Target Protein for PROTAC, LigandsforTargetProteinforPROTAC, ligase, inhibit, lymphoma, Navitoclax piperazine, Navitoclaxpiperazine, Navitoclax-piperazine, Inhibitor, Target Protein-binding Moiety, VHL, ubiquitin

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

132020434 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols